Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu-177-EDTMP and Sm-153-EDTMP cocktail for palliation of metastatic bone pain
IRCT20180203038601N1Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Jun 2017
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of samarium-153 lexidronam in bone metastases, sponsored by Shiraz University of Medical Sciences. Primary endpoint: Level of pain caused by bone metastases. Started Jun 2017; status: completed.
02
Drugs
samarium-153 lexidronam
03
Conditions
bone metastases
Beyond the preview
Go deeper on IRCT20180203038601N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180203038601N1.